African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials

Yan Zhou1, David Elashoff2, Sarah Kremen2, Edmond Teng2,3, Jason Karlawish4, Joshua D. Grill5
1American Board of Anesthesiology, Raleigh, NC, USA
2Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
3VA Greater Los Angeles Healthcare System, Los Angeles, CA USA
4Departments of Medicine and Medical Ethics and Health Policy, Alzheimer's Disease Core Center, Penn Neurodegenerative Disease Ethics and Policy Program, University of Pennsylvania, Philadelphia, PA, USA
5Department of Psychiatry and Human Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA

Tóm tắt

AbstractIntroductionAlzheimer's disease (AD) incidence is disproportionately high in African Americans, yet, recruitment of this community to AD clinical trials is challenging.MethodsWe compared 47 African Americans and 78 whites in their willingness to enroll in a hypothetical preclinical AD trial and examined barriers and facilitators in their decision making.ResultsAfrican American race (OR = 0.45; 95% CI, 0.22–0.93) and score on the research attitude questionnaire (OR = 1.12; 95% CI, 1.04–1.22) were independently associated with willingness to participate. African Americans rated study risks, the requirement of a study partner, study procedures, the ratio of drug to placebo, and study location as more important factors in the decision whether to enroll than did whites.DiscussionThese results suggest that researchers will encounter challenges in recruiting African Americans to preclinical AD trials. Future research will be necessary to understand the optimal means to improve recruitment of underrepresented populations.

Tài liệu tham khảo

10.1016/j.jalz.2015.12.007 Yaffe K., 2013, Effect of socioeconomic disparities on incidence of dementia among biracial older adults: Prospective study, BMJ, 347, 10.1136/bmj.f7051 10.1001/archneur.60.2.185 10.1159/000109998 10.1111/j.1532-5415.2006.00747.x 10.1212/WNL.56.1.49 10.1111/j.1532-5415.2005.53569.x 10.1111/j.1532-5415.2009.02395.x 10.1097/WAD.0b013e318192e94d 10.1212/01.wnl.0000167545.38161.48 10.1212/01.wnl.0000334278.11022.42 10.1212/01.wnl.0000285287.99923.3c 10.1017/S104161020700511X 10.1377/hlthaff.2013.1314 10.1126/scitranslmed.3007941 10.1097/00002093-199904001-00008 10.1097/00002093-200200002-00009 10.1016/j.neurobiolaging.2015.11.007 10.1093/geront/gnp023 10.1525/jer.2011.6.1.63 10.1097/00002093-200007000-00003 10.3233/JAD-150729 10.1177/1525822X02239569 Team RC, 2015, R: A Language and Environment for Statistical Computer 10.1097/WAD.0000000000000016 10.1371/journal.pmed.0030019 10.1097/WAD.0b013e3181f12432 10.1046/j.1525-1497.1999.07048.x 10.1177/0898264304268151 10.1097/WAD.0b013e3181f14a14 Harris Y., 1996, Why African Americans may not be participating in clinical trials, J Natl Med Assoc, 88, 630 10.1037/0022-006X.64.5.875 Neugroschl J., 2016, Attitudes and Perceptions of Research in Aging and Dementia in an Urban Minority Population, J Alzheimers Dis, 53, 69, 10.3233/JAD-151072 Jefferson A.L., 2011, Clinical research participation among aging adults enrolled in an Alzheimer's Disease Center research registry, J Alzheimers Dis, 23, 443, 10.3233/JAD-2010-101536 10.1097/00002093-200301000-00003 10.1089/109065703321560921 Manly J.J., 1999, Alzheimer's Disease Among Different Ethnic and Racial Groups. Alzheimer's Disease, 2nd ed, 117 Satcher D., 2014, More African Americans Need to Participate in Clinical Trials 10.1126/scitranslmed.aaf0946 Romero H.R., 2014, Community engagement in diverse populations for Alzheimer disease prevention trials, Alzheimer Dis Assoc Disord, 28, 269, 10.1097/WAD.0000000000000029 10.1097/01.wad.0000190808.97878.b8